Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.

The pharmaceutical company is cutting thousands of jobs as it restructures amid pressure from antitrust allegations in the ...

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the ...

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

Far fewer companies are letting employees go so far in 2026 compared to 2025, but the number of people affected is trending ...

Massachusetts' largest pharmaceutical company just got hit with an $885 million verdict — but the final bill may actually top ...

With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...

A federal jury found Takeda Pharmaceuticals Co. Ltd. liable for violating antitrust law by delaying the generic version of its branded Amitiza drug through an illegal agreement with a competitor, ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

A U.S. jury found Takeda Pharmaceutical responsible for $885 million in damages, ruling they delayed a generic version of ...

A U.S. federal jury has ordered Japan-based Takeda Pharmaceutical to pay approximately $885 million in damages after finding the company liable for delaying the release of a generic version of its ...